About

Overview

Brenden Rabinovitch is a neuroscientist-in-training with broad interests including psychedelics, amphetamines, cannabis, neural circuits, and brain network disorders. He has training in electrophysiology and neuropharmacology. His expertise lies in preclinical animal studies of anti-seizure medications (ASMs) and understanding mechanisms of brain network changes. Brenden has experience working with preclinical animal models of autism spectrum disorder (ASD), epilepsy and acute seizures, and drug-brain interactions.

​

Currently, Brenden is pursuing his Master's of Science (MSc) in Physiology, studying the anti-convulsant effects of minor cannabinoids in combination with cannabidiol (CBD) on seizures. He is also studying the effects of lysergic acid diethylamide (LSD) on electrophysiological brain activity.

​

Academic appointments & positions

Since 2019, Brenden has been the Head of Research at the Neurology Centre of Toronto (NCT), an outpatient research-oriented neurology clinic in Toronto. Here, he leads projects studying the clinical efficacy of medical cannabis in treating pediatric and adult epilepsy and other neurological conditions. He also aided in the development of NCT's Virtual Rapid Access Clinics (VRACs).

​

Currently, Brenden is a Graduate Student (MSc) at the Krembil Brain Institute, He is conducting his basic neurophysiology and neuropharmacology research.

 

In 2024, Brenden joined Pneuma Science as an Associate Researcher, where he is working on open-label trials, retrospective reports, and case studies examining the efficacy of psychedelics in treating mental health conditions, such as functional neurological disorder (FND), major depression/treatment-resistant depression, post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI).

​

Private industry

Brenden is a Scientific Advisor for Medole Inc. This is an unpaid advisory role.